|Bid||8.15 x 0|
|Ask||8.20 x 0|
|Day's Range||8.13 - 8.37|
|52 Week Range||7.65 - 49.95|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 21, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BIOVIC-B.ST
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) DiviTum® TKa ready for clinical use in the US
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2022, and the Chairman of the Board.
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company's test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market.